CANF Company Profile and Key Details
Can-Fite BioPharma
Price Chart
Stock Price Today
Can-Fite BioPharma Ltd. (CANF) stock surged +5.20%, trading at $4.25 on AMEX, up from the previous close of $4.04. The stock opened at $4.10, fluctuating between $4.10 and $4.46 in the recent session.
Stock Snapshot
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Feb 05, 2026 | 4.10 | 4.50 | 4.10 | 4.25 | 521.92K |
| Feb 04, 2026 | 4.25 | 4.27 | 4.04 | 4.04 | 16.43K |
| Feb 03, 2026 | 4.13 | 4.17 | 4.00 | 4.05 | 21.54K |
| Feb 02, 2026 | 4.16 | 4.32 | 4.05 | 4.13 | 23.55K |
| Jan 30, 2026 | 4.00 | 4.18 | 4.00 | 4.01 | 18.97K |
| Jan 29, 2026 | 4.37 | 4.55 | 4.10 | 4.10 | 24.19K |
| Jan 28, 2026 | 4.53 | 4.53 | 4.35 | 4.43 | 15.68K |
| Jan 27, 2026 | 4.38 | 4.64 | 4.34 | 4.47 | 42.22K |
| Jan 26, 2026 | 4.47 | 4.60 | 4.32 | 4.34 | 50.44K |
| Jan 23, 2026 | 4.23 | 4.60 | 4.17 | 4.47 | 72.51K |
| Jan 22, 2026 | 4.08 | 4.39 | 3.98 | 4.16 | 94.96K |
| Jan 21, 2026 | 4.02 | 4.15 | 3.91 | 4.08 | 58.59K |
| Jan 20, 2026 | 4.10 | 4.17 | 3.87 | 3.99 | 231.14K |
| Jan 02, 2026 | 76.00 | 88.00 | 74.40 | 88.00 | 6.7K |
| Dec 31, 2025 | 73.88 | 80.92 | 71.52 | 80.00 | 8.41K |
| Dec 30, 2025 | 68.60 | 79.88 | 67.60 | 73.40 | 10.4K |
| Dec 29, 2025 | 79.04 | 84.00 | 67.12 | 68.60 | 14.51K |
| Dec 26, 2025 | 108.28 | 109.40 | 84.00 | 85.56 | 435.69K |
| Dec 24, 2025 | 80.00 | 80.92 | 68.00 | 72.12 | 9.45K |
| Dec 23, 2025 | 100.40 | 100.40 | 93.36 | 96.20 | 1.62K |
Contact Details
About Company
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
Company Information
| Employees | 5 |
| Beta | 0.04 |
| Sales or Revenue | $743.00K |
| 5Y Sales Change% | -0.994% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
Company Overview
Technical Performance
Shareholding & Insider Activity
Financial & Profitability Overview
On valuation metrics, Can-Fite BioPharma trades at a P/E of -0.28, P/S of 4.09 and P/B of 0.58. The current ratio is 3.60 and quick ratio is 3.60. Debt-to-equity is 0.02, supported by a cash flow-to-debt ratio of -92.81.
Quarterly Financial Highlights
The company ended the quarter with $8.92M in cash and short-term investments, a total debt of $40.00K, and net debt of - $4.24M. Total assets were $9.99M, with equity of $6.24M. Financials further reflected weakness, with operating cash flow of - $8.44M, free cash flow of - $8.44M, and capital expenditures of - $2.00K.
Frequently Asked Questions
Senior Clinical Advisor
Dr. Sari Fishman Ph.D.
Vice President of Bus. Devel.
Dr. Pnina Fishman Ph.D.
Founder, Chief Scientific Officer & Executive Chairman
Dr. Vibeke S. Strand FACP, FACR, FACR (USA), M.D.
Senior Clinical Advisor
Mr. Motti Farbstein
Chief Executive Officer & Chief Operating and Financial Officer
Dr. Ilan Cohn Ph.D.
Co-Founder & Director
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep